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Abstract
We analyzed 115 iliac crest bone marrow biopsy specimens from 101 patients with metastatic castration-
resistant prostate cancer, divided into a test (n [ 57) and a validation (n [ 58) set. We developed a score
based on computed tomography Hounsﬁeld units and lactate dehydrogenase levels, which were associated
with a positive biopsy result. The score can be used to select patients for whom a bone marrow biopsy will
provide tissue for molecular characterization.
Background: The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment
has been constrained by the disease’s predilection to metastasize primarily to bone. We hypothesized that the use of
clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies (BMBs). We aimed to
develop a score for the selection of patients undergoing BMB. Materials and Methods: A total of 115 BMBs were
performed in 101 patients: 57 were included in a derivation set and 58 were used as the validation set. The clinical and
laboratory data and prebiopsy computed tomography parameters (Hounsﬁeld units [HUs]) were determined. A score
for the prediction of biopsy positivity was developed from logistic regression analysis of the derivation set and tested
in the validation set. Results: Of the 115 biopsy specimens, 75 (62.5%) were positive; 35 (61.4%) in the test set and 40
(69%) in the validation set. On univariable analysis, hemoglobin (P ¼ .019), lactate dehydrogenase (P ¼ .003), prostate-
speciﬁc antigen (P ¼ .005), and mean HUs (P ¼ .004) were selected. A score based on the LDH level ( 225 IU/L) and
mean HUs ( 125) was developed in multivariate analysis and was associated with BMB positivity in the validation set
(odds ratio, 5.1; 95% conﬁdence interval, 1.9%-13.4%; P ¼ .001). The area under the curve of the score was 0.79 in
the test set and 0.77 in the validation set. Conclusion: BMB of the iliac crest is a feasible technique for obtaining tumor
tissue for genomic analysis in patients with castration-resistant prostate cancer metastatic to the bone. A signature
based on the mean HUs and LDH level can predict a positive yield with acceptable internal validity. Prospective
studies of independent cohorts are needed to establish the external validity of the score.
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Figure 1 Computed Tomography Parameters in the Posterior
Iliac Crest
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CRPC Tissue Acquisition for Molecular AnalysisIntroduction
Prostate cancer is currently the second most common cancer in
men, accounting for 15% of male cancer cases. Prostate cancer is the
ﬁfth leading cause of death in men worldwide (6.6% of total deaths)
and is a major cause of morbidity.1 Death from this disease follows
the development of metastatic castration-resistant prostate cancer
(mCRPC), for which no validated predictive molecular biomarkers
to aid treatment selection are available to date. The low cost and
high throughput evaluation of tumor genomes and transcriptomes
is, nevertheless, rapidly enabling unprecedented opportunities to
pursue the study of putative predictive tumor biomarkers. This is
especially critical as the intra- and interpatient heterogeneity of the
prostate cancer genome is described.2,3
We have previously described how the optimal evaluation of
novel agents for the treatment of mCRPC requires the pursuit of a
pharmacologic audit trail.4-6 The pharmacologic audit trail involves
the study of putative predictive biomarkers for patient selection, the
evaluation of pre- and post-treatment normal tissue, and tumor
biopsy evaluation of target modulation by medication, and rean-
alysis of the tumor at disease progression after a response to deter-
mine the mechanisms of resistance. Critical to this is access to tumor
tissue, although it is hoped that the molecular characterization of
circulating biomarkers such as messenger RNA,7 circulating tumor
DNA,8-10 and/or circulating tumor cells11-13 will also have clinical
utility.
Up to 90% of patients with advanced prostate cancer will have
disease metastatic to the bone, with most having disease involving
the pelvis. Assessment of disease in the bone, which is commonly
performed by bone scintigraphy, is, at best, suboptimal. Scintig-
raphy currently provides no qualitative information on the activity
of the lesions, and progression is determined exclusively by the
appearance of new tracer uptake. Technological advances in the
processing of tissue from bone biopsies has enabled the performance
as a valid approach for tissue acquisition from these patients.14
Moreover, DNA and RNA sequencing from bone biopsy speci-
mens is now technically feasible.15 Such biopsies are being
increasingly undertaken and even mandated in clinical trials. We
hypothesized that the yield of CRPC tissue from bone biopsies
could be increased by routine and inexpensive, nonsimultaneous
imaging guidance using computed tomography (CT) and clinical
parameters. A previous report on iliac crest CRPC bone biopsies
yielded 25% positive samples without imaging guidance, with lower
hemoglobin, greater alkaline phosphatase, and greater lactate de-
hydrogenase (LDH) levels associatinzg with increased yield.16 A
more recent report evaluating the effect of abiraterone acetate on
androgen signaling in bone metastases had a positive yield in 47%
of bone biopsies undertaken.17 Studies evaluating bone biopsies
performed under simultaneous CT guidance reported a positive
yield of  67%.15 Differences in bone density parameters on pelvic
CT scans (Hounsﬁeld units [HUs]), indicating sclerotic bone re-
action associated with malignant inﬁltration, have also been
reported.15
In the present study, we evaluated the association of clinical
and radiologic factors with bone marrow biopsy (BMB) positivity.
We propose a model that can predict the success rate and maxi-
mize tumor tissue acquisition for biomarker evaluation andnical Genitourinary Cancer Month 2016molecular characterization in developmental therapeutic agents for
CRPC.
Materials and Methods
Patient Population
Patients with mCRPC who undergone a BMB from October
2011 to November 2014 at the Royal Marsden National Health
Services Foundation Trust (Sutton, UK) were retrospectively
identiﬁed. The criteria for inclusion in the present study were
CRPC, age  18 years, and evidence from imaging studies (CT,
bone scan, or magnetic resonance imaging) of bone metastases from
prostate cancer. Patients with a CT scan of the pelvis performed > 6
weeks before the biopsy were excluded. The clinical and imaging
parameters were retrospectively collected from the electronic patient
records. All patients provided informed consent before undergoing
biopsy. The method for image acquisition (CT scanner) remained
consistent throughout the study.
Tissue Acquisition and Analysis
Tissue was collected using a bone trephine biopsy from the right
or left posterior iliac crest. No image guidance was used for tissue
acquisition. Biopsies were performed using 8-gauge (3.05-mm)
needles. The biopsy specimens were sealed in a container with a 10%
paraﬁlm solution and ﬁxed at room temperature for 24 to 30 hours
with agitation. After ﬁxing the samples, they were brieﬂy rinsed in
distilled water, placed in a container of ethylenediaminetetraacetic
acid (EDTA) solution, sealed, and incubated for about 48 hours at
37C. The EDTA solution was prepared by (1) dissolving 50 g of
sodium hydroxide in 3500 mL of distilled water; (2) adding EDTA;
and (3) stirring until the solution cleared. The pH of the solution
was checked and adjusted to 7.0 each day the solution was used.
Next, 2-mm-thick sections were stained with hematoxylin-eosin
(Figure 1) and analyzed by 1 pathologist (D.N.R.), who was un-
aware of the clinical and imaging data. Cases were considered
negative when no intact tumor cells could be identiﬁed. Positive
cases, with intact tumor cells identiﬁed, were classiﬁed into those
showing < 50 cells and those showing  50 cells.
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Patients with a CT scan of the pelvis performed > 6 weeks before
the biopsy were excluded from the analyses. The images were
analyzed by an experienced radiologist (N.T.) specializing in the
ﬁeld of prostate cancer. An area with a diameter of 0.8 to 1 cm
(depending on the patient’s anatomy) was drawn in the posterior
aspect of the iliac crest in a region thought to be representative of
the biopsied area; the location was equivalent for all patients. The
mean HU of the biopsy site (left or right) was determined in 3
consecutive slices (5 mm thickness), and the average value was used
in the analyses (Figure 2). The bone scans were reviewed for the
presence of metastatic disease in the iliac crests and to estimate the
bone tumor burden, classiﬁed as < 5 bony sites, 5 to 20 bone
metastases, or > 20 metastases, indicating widespread disease.
Statistical Analysis
A descriptive analysis of the baseline laboratory and imaging
features was performed, and the median and interquartile range
(IQR) are reported. Random assignment algorithms were used to
allocate biopsies to the test or the validation group. The test group
was used to obtain a model for the prediction of positivity in BMBs.
The dependent variable of the model (bone marrow positivity) was
deﬁned as the presence of tumor in the processed tissue. The cutoff
values for dichotomous variables were established from the test set.
Those that presented with greater receiver operating characteristic
(ROC) area under the curve (AUC) values were selected for
development of the predictive model, which was validated in the
second, validation group. The mean values of the baseline param-
eters between the groups were compared using the Student t test.
Univariable analyses were performed using logistic regression
models with only 1 covariate. Variables with a statistically signiﬁcant
association to the dependent variable (P < .05) were selected forFigure 2 Hematoxylin and Eosin Staining of a Positive Bone
Marrow Biopsyinclusion in a multivariable logistic regression model, with bone
marrow positivity as the dependent variable. Internal validity of the
model was tested by establishing the ROC AUC in the test set
(Figure 3). External validity was established by determining the
ROC AUC in the validation set (Figure 3). Statistical signiﬁcance
was determined by testing the obtained AUCs against a null hy-
pothesis of 0.5. The sensitivity, speciﬁcity, and positive and negative
predictive values of the model were determined in the test and
validation sets. The observed positivity rate of the biopsy specimens
in the whole cohort was used as the prevalence value for the
calculation of the predictive values. The score was then tested for its
association with bone marrow positivity, deﬁned as biopsy speci-
mens yielding  50 tumor cells using logistic regression modeling.
All statistical procedures were performed using SPSS Statistics,
version 20 (IBM Corp., Armonk, NY).
Results
Samples and Patient Characteristics
A total of 115 biopsies in 101 patients were performed from
October 19, 2011 to November 11, 2014. Overall, 75 biopsies
(65.2%) were positive. Of these, 20 biopsies (26.7%) yielded < 50
cells and 55 biopsies (73.3%) > 50 cells. The biopsy cores had a
median length of 17 mm (IQR, 12-22 mm). Of the 115 biopsies,
67 (58.3%) were acquired from the right pelvis and 48 (41.7%)
from the left pelvis. The median interval from the CT scan to the
performance of the biopsy was 14 days (IQR, 4-28 days). Of the
101 patients, 83 (72.2%) had received previous docetaxel and 80
(69.6%) had received previous abiraterone. Details of the last
treatment before the biopsy are summarized in Table 1. In 34 bi-
opsies (29.6%), the patients had undergone previous radiotherapy
to the pelvis, and in 33 biopsies (28.7%), the patients had received
previous bone targeting agents (Table 1). In total, 27 patients
(23.5%) were using opioids for the treatment of bone metastatic
pain at biopsy and 70.3% of patients had been revealed to have
> 20 bone metastases on the bone scan.
Of the 115 biopsy specimens, 57 were included in the test set
and 58 were included in the validation set. The baseline laboratory
and CT (mean HU) parameters in the test and validation sets are
listed in Table 2. Of the 57 biopsy specimens in the test set and 58
in the validation set, 35 (61.4%) in the test set and 40 (69%) in the
validation set were positive; with no signiﬁcant differences between
the 2 groups (P ¼ .395). The test and validation cohorts had similar
prognostic baseline laboratory and CT parameter distributions, with
no statistically signiﬁcant differences.
Uni- and Multivariable Analysis (Test Set)
Of the 57 biopsy specimens in the test set, 35 (61.4%) were
classiﬁed as positive for tumor content. The variables were ﬁrst tested
as continuous variables (Table 3). Only the baseline LDH
(P ¼ .006) and baseline prostate-speciﬁc antigen (P ¼ .006) levels
were signiﬁcantly associated with positive biopsy results. Continuous
variables were dichotomized and tested in univariable logistic
regression models (Table 4). The type of previous anticancer treat-
ment (P¼ .705), use of previous pelvic radiotherapy (P¼ .120), and
previous bisphosphonate use (P ¼ .975) were not associated with
biopsy positivity. Low hemoglobin levels ( 11.5 g/dL vs. < 11.5
g/dL; P ¼ .019), high LDH levels ( 225 IU/L vs. < 225 IU/L;Clinical Genitourinary Cancer Month 2016 - 3
Figure 3 Receiver Operating Characteristic Curve Analysis of the Test and Validation Sets
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Table 1 Clinical Characteristics
Characteristic n (%)
Total patients 115 (100)
Last treatment before BMB
Hormonal agentsa 70 (60.9)
Chemotherapyb 28 (24.3)
Other (investigational agents; phase
I/II clinical trials)
17 (14.8)
Previous bone targeting agents
None 82 (71.3)
Bisphosphonates 27 (23.5)
Radium-223 1 (0.9)
Strontium 3 (3.6)
Cabozantinib 1 (0.9)
Samarium 1 (0.9)
Previous RT to pelvis
Yes 35 (30.4)
No 80 (69.6)
Pain requiring opioids
Yes 27 (23.5)
No 88 (76.5)
Abbreviation: RT ¼ radiotherapy.
aAbiraterone, enzalutamide, bicalutamide, goserelin, and dexamethasone.
bDocetaxel, cabazitaxel.
Table 3 Univariate Analysis (Test Set) Results: Continuous
Variables
Variable HR (95% CI) P Value
Hemoglobin 0.53 (0.14-1.95) .340
Platelets 0.75 (0.2-2.75) .663
Neutrophils 2.44 (0.57-10.5) .231
Lymphocytes 1.06 (0.36-3.12) .922
NLR 1.3 (0.52-3.2) .575
LDH 32.4 (2.69-391.6) .006a
ALP 1.52 (0.77-3.02) .231
Albumin 0.89 (0.76-1.03) .113
PSA 1.92 (1.2-3.04) .006a
Mean HU 1.01 (0.57-2.11) .78
Hemoglobin, platelets, neutrophils, lymphocytes, NLR, LDH, ALP, PSA, and mean HUs were log-
transformed.
Abbreviations: ALP ¼ alkaline phosphatase; CI ¼ conﬁdence interval; HR ¼ hazard ratio;
HUs ¼ Hounsﬁeld units; LDH ¼ lactate dehydrogenase; NLR ¼ neutrophil-to-lymphocyte ratio;
PSA ¼ prostate-speciﬁc antigen.
aStatistically signiﬁcant.
David Lorente et alP ¼ .003), PSA levels ( 225 vs. < 225 ng/mL; P ¼ .005), high
alkaline phosphate levels ( 100 vs. < 100 IU/L; P ¼ .025), and
high mean HUs on CT ( 125 HU vs. < 125 HU; P ¼ .004) were
signiﬁcantly associated with a positive BMB and were selected for
multivariable analysis. On multivariable analysis, only mean HUs 
125 (odds ratio [OR], 3.85; 95% conﬁdence interval [CI], 1.06-
13.94; P¼ .036) and elevated LDH 225 IU/L (OR, 8.7; 95% CI,
1.68-45.11; P ¼ .003) were signiﬁcantly associated with BMB
positivity (Table 5).
Predictive Score: Performance in Test and Validation Sets
From the results of the multivariable analysis in the test set, a
score (BMB score) was developed by assigning 1 point to each of theTable 2 Baseline Laboratory and Computed Tomography Parameter
Variable All Biopsies (n [ 115) Test Set (n
Hemoglobin (g/L) 11.3 (10.7-12.8) 11.6 (10.8-1
Platelets 220 (176-270) 220 (169-2
Neutrophils 3.8 (3-5.1) 3.8 (3-5.1)
Lymphocytes 1.1 (0.8-1.4) 1.1 (0.8-1.
NLR 3.6 (2.4-6.1) 3.6 (2.1-6.
ALP (IU/L) 172 (96-423) 205 (95-34
Albumin (g/L) 36 (33-38) 36 (33-38
LDH (IU/L) 196 (166-255) 198 (165.5
PSA (ng/mL) 212 (94-500) 212 (96.5-6
Mean HU 136.5 (27.5-235.8) 144 (42-24
Data presented as mean (range).
Abbreviations: ALP ¼ alkaline phosphatase; HUs ¼ Hounsﬁeld units; LDH ¼ lactate dehydrogenase
aStudent t test for equivalence of mean values.parameters (0 points if neither the HUs were  125 nor the LDH
was  200; 1 point if either the HU was  125 or LDH was
 200; and 2 points if both the HUs were  125 and the LDH was
 200). The score was signiﬁcantly associated with bone marrow
positivity in both the test (OR, 5.4; 95% CI, 2.1-13.7; P < .001)
and validation (OR, 5.1; 95% CI, 1.9-13.4; P ¼ .001) sets. In the
validation set, the score was associated with a positive result, inde-
pendent of other parameters (Tables 6 and 7). In the test set, only
23.5% of the biopsies with a score of 0 were positive compared with
77.5% of the biopsies with a score of 1 to 2 (P< .001). Similarly, in
the validation set, only 21.4% of the biopsies with a score of 0 were
positive for tumor content compared with 84.1% of biopsies with a
score of 1 to 2 (P < .001). The AUC of the BMB score was 0.79
(95% CI, 0.67-0.91; P < .001) in the test and 0.77 (95% CI, 0.59-
0.88; P < .001) in the validation set.
Sensitivity, Speciﬁcity, and Predictive Values
We established the sensitivity, speciﬁcity, and predictive values
of each of the parameters in the model. The global positivity
rate (65.2%) was used to calculate positive and negatives
[ 57) Validation Set (n [ 58) P Valuea
2.8) 11.3 (10.6-12.8) .868
76) 220 (181-269) .911
3.8 (2.9-5.2) .906
5) 1.1 (0.8-1.4) .817
3) 3.2 (2.4-6.1) .685
5) 167 (105-450) .546
) 36 (33-37) .268
-265.5) 195.5 (168-252) .310
09) 205 (85-455) .215
1) 114 (5-230.5) .282
; NLR ¼ neutrophil-to-lymphocyte ratio; PSA ¼ prostate-speciﬁc antigen.
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Table 4 Univariate Analysis (Test Set) Results: Categorical
Variables (Cutoff Values)
Variable Positive (%) OR (95% CI) P Value
Hemoglobin 0.25 (0.08-0.8) .019a
<11.5 77.8 (21/27)
11.5 46.7 (14/30)
Platelets 0.97 (0.32-2.93) .953
<200 61.9 (13/21)
200 61.1 (22/36)
Neutrophils 2.03 (0.69-6) .200
<3.5 52 (13/25)
3.5 68.8 (22/32)
Lymphocytes 1.41 (0.48-4.17) .534
<1 56.5 (13/23)
1 64.7 (22/34)
NLR 2.08 (0.68-6.35) .197
<3 50 (10/20)
3 67.6 (25/37)
LDH 11.3 (2.27-56) .003a
<225 44.4 (16/36)
225 90.5 (19/21)
PSA 5.75 (1.72-19.3) .005a
<225 43.3 (13/30)
225 81.5 (22/27)
ALP 4.03 (1.2-13.6) .025a
<100 37.5 (6/16)
100 70.7 (29/41)
Albumin 0.44 (0.13-1.47) .441
<34 73.7 (14/19)
34 55.3 (21/38)
Mean HU 5.78 (1.76-18.93) .004a
<125 35 (7/20)
125 75.7 (28/37)
Treatment before
biopsy
0.87 (0.42-1.81) .705
Hormonal 62.5 (20/32)
Chemotherapy 64.7 (11/17)
Other 50 (4/8)
Previous pelvic RT 0.4 (0.12-1.27) .120
Yes 47.1 (8/17)
No 67.5 (27/40)
Bisphosphonates 0.98 (0.31-3.1) .975
Yes 61.5 (24/39)
No 61.1 (11/18)
Strong opioids 1.29 (0.27-6.16) .751
Yes 66.7 (7/12)
No 57.8 (26/45)
Abbreviations: ALP ¼ alkaline phosphatase; CI ¼ conﬁdence interval; HU ¼ Hounsﬁeld unit;
LDH ¼ lactate dehydrogenase; NLR ¼ neutrophil-to-lymphocyte ratio; OR ¼ odds ratio; PSA ¼
prostate-speciﬁc antigen; RT ¼ radiotherapy.
aStatistically signiﬁcant.
Table 5 Multivariate Analysisa (Test Set) Results
Variable OR (95% CI) P Valuea
Hemoglobin 0.68 (0.15-3.02) .610
LDH 8.7 (1.68-45.11) .003b
ALP 2.06 (0.47-9.03) .336
PSA 2.79 (0.7-11.12) .144
Mean HU 3.85 (1.06-13.94) .036b
Abbreviations: ALP ¼ alkaline phosphatase; CI ¼ conﬁdence interval; HU ¼ Hounsﬁeld unit;
LDH ¼ lactate dehydrogenase; NLR ¼ neutrophil-to-lymphocyte ratio; OR ¼ odds ratio; PSA ¼
prostate-speciﬁc antigen.
aBackward stepwise logistic regression, with P values calculated according to change in log-
likelihood.
bStatistically signiﬁcant.
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(0.80 in the test set; 0.88 in the validation set) and the LDH level
had greater speciﬁcity (0.90 in the test and 0.78 in the validation
set). The BMB score (0 vs. 1-2) showed a high sensitivity (0.89 in
the test and 0.93 in the validation sets), with relatively low speci-
ﬁcity (0.59 in the test set and 0.61 in the validation set; Table 8).
Ability of the BMB Score to Predict Biopsy Yield of  50
Cells
The biopsy specimens were further classiﬁed into those
yielding  50 cells and < 50 cells, because of previous reports ofTable 6 Bone Marrow Biopsy Score: Uni- and Multivariable
Analysis Results
Variable OR (95% CI) P Value
Univariate analysis
(validation set)
BMB score 5.07 (1.9-13.4) .001a
Hemoglobin 0.34 (0.11-1.08) .068
Platelets 0.93 (0.29-3) .900
Neutrophils 1.20 (0.39-3.69) .751
Lymphocytes 0.47 (0.14-1.57) .470
NLR 1.53 (0.5-4.68) .458
PSA 3.18 (0.95-10.6) .060
ALP 1.54 (0.42-5.59) .513
Albumin 0.42 (0.1-1.69) .220
Previous pelvic RT 1.63 (0.44-5.98) .465
Bisphosphonates 1.45 (0.34-6.16) .613
Strong opioids 1.43 (0.38-5.48) .598
Multivariate analysis
(validation set)
BMB score 4.18 (1.55-11.25) .005
Hemoglobin 0.55 (0.14-2.06) .372
ALP 1.17 (0.25-5.39) .844
PSA 2.05 (0.53-7.99) .300
Abbreviations: ALP ¼ alkaline phosphatase; BMB ¼ bone marrow biopsy; CI ¼ conﬁdence
interval; HU ¼ Hounsﬁeld unit; LDH ¼ lactate dehydrogenase; NLR ¼ neutrophil-to-
lymphocyte ratio; OR ¼ odds ratio; PSA ¼ prostate-speciﬁc antigen; RT ¼ radiotherapy.
aStatistically signiﬁcant.
Table 7 BMB Score: Categorical Analysis Results for Test and Validation Sets
BMB Results
Test Set Validation Set
Positive BM (%) OR (95% CI)a P Value Positive BM (%) OR (95% CI)a P Value
Any positive cells
0 4/17 (23.5) — — 3/14 (21.4) — —
1 15/22 (68.2) 7 (1.7-171.2) .008 21/25 (84) 19.3 (3.6-101.7) < .001
2 16/18 (88.9) 20 (4.1-165.1) .001 16/19 (84.2) 19.6 (3.3-115.4) .001
Total 35/57 (61.4) — — 40/58 (69) — —
50 Cells
0 1/17 (5.9) — — 2/14 (14.3) — —
1 12/22 (54.5) 19.2 (2.15-171.5) .008 16/25 (64) 10.7 (1.9-58.7) .007
2 10/18 (55.6) 20 (2.16-184.9) .008 14/19 (73.7) 16.8 (2.7-102.9) .002
Total 23/57 (40.4) 26/58 (55.2)
Abbreviations: BM ¼ bone marrow; BMB ¼ bone marrow biopsy; CI ¼ conﬁdence interval; OR ¼ odds ratio.
aBMB score of 0 used as a reference for logistic regression analysis.
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samples. In those studies, biomarker status had only been consid-
ered in those biopsy specimens containing  50 cells.18 In our
studies, 23 biopsy specimens (40.4%) in the test set and 32 (55.2%)
in the validation set contained  50 cells. The BMB score was
associated with positivity ( 50 cells) in both the test (OR, 3.1;
95% CI, 1.41-6.84; P ¼ .005) and the validation (OR, 3.7; 95%
CI, 1.6-8.4; P ¼ .002) sets. The AUC of the BMP score was 0.72
(95% CI, 0.58-0.85) in the test set and 0.73 (95% CI, 0.59-0.86)Table 8 Sensitivity, Speciﬁcity, and Predictive Values
Variable
Estimate (95% CI)
Test Set Validation Set
BMB score (0 vs. 1-2)
Sensitivity (%) 88.6 (74-95.5) 92.5 (80.1-97.4)
Speciﬁcity (%) 59.1 (38.7-76.7) 61.1 (38.6-79.7)
Positive predictive
value (%)
78.3 (68.3-85.8) 79.9 (68.8-82.8)
Negative predictive
value (%)
75.6 (53.7-89.3) 83 (60.8-93.9)
Mean HU  125
Sensitivity (%) 80 (64.1-90) 87.5 (73.9-94.5)
Speciﬁcity (%) 59.1 (38.7-76.7) 66.7 (43.7-83.7)
Positive predictive
value (%)
75.7 (59.8-86.6) 85.4 (71.6-93.2)
Negative predictive
value (%)
65 (43.3-81.8) 70.6 (46.9-86.7)
LDH  225 IU/L
Sensitivity (%) 54.3 (38.2-69.5) 45 (30.7-60.2)
Speciﬁcity (%) 90.1 (72.2-97.5) 77.8 (54.8-91)
Positive predictive
value (%)
90.5 (71.1-97.4) 81.8 (61.5-92.7)
Negative predictive
value (%)
55.6 (39.6-70.5) 38.9 (24.8-55.1)
Abbreviations: BMB ¼ bone marrow biopsy; CI ¼ conﬁdence interval; HU ¼ Hounsﬁeld unit;
LDH ¼ lactate dehydrogenase.in the validation set. In the validation set, only 2 biopsy specimens
(14.3%) with a score of 0 had  50 cells but 30 (68.2%) of those
with a score of 1 to 2 were positive.
Discussion
With the advent of novel agents for the treatment of CRPC and
the improved understanding of the molecular biology mechanisms
driving disease progression beyond castration, the improvement of
mechanisms for tissue acquisition and molecular analysis has
become of paramount importance. Up to 89% of patients with
mCRPC might harbor clinically actionable genomic aberrations.19
Furthermore, despite signiﬁcant interpatient heterogeneity, the
alterations in known oncogenic drivers have been highly concordant
within the individual’s metastatic sites. Assessing single metastasis
through soft tissue biopsies or BMBs could therefore provide a
reasonable assessment of the oncogenic landscape and prove infor-
mative for treatment selection.3
The propensity to spread to the bones (in many cases, the only
metastatic site) is a distinct characteristic of prostate cancer. Thus, a
large proportion of patients do not have soft tissue metastases
amenable for biopsy. A number of studies published in the past
decade have reported variable rates of positive BMBs ranging from
25% to 50% for nonimaging-guided biopsies16,17,20 and increasing
to 67% to 77% when performed under direct CT guidance.15,21
Our cohort, with biopsies performed without direct CT guidance,
had a bone biopsy positivity rate of 62.5%, consistent with the
ﬁndings from previous reports.
Previous studies have established associations among the clinical,
analytical, and CT parameters with BMB positivity.16,21 The pre-
sent study, however, is the ﬁrst study to establish the value of the
widely used CT and analytical parameters and develop a score with
direct applicability in the clinical setting, with validation of these
results in a separate control group. We have proved the predictive
potential of a simple score that can help select patients likely to
provide enough tissue for molecular analyses such as exome and
transcriptome next-generation sequencing, which is now becoming
embedded in many of our therapeutic trials in CRPC. In a recently
published multi-institutional CRPC genomic sequencing project,19Clinical Genitourinary Cancer Month 2016 - 7
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8 - Cli29% of all sequenced tissue was from bone metastases, highlighting
the importance of adequate patient selection for the performance of
BMBs.
The high sensitivity of the BMB score supports its use for the
identiﬁcation of patients with a low likelihood of a positive result.
We would therefore recommend not performing the procedure in
patients with a score of 0 (ie, if the bone density of the iliac crest
does not exceed a HU of 125 and the LDH levels are < 225 IU/L).
In such cases, the probability of achieving a negative result (negative
predictive value) is about 76% to 83% compared with a 78% to
79% chance of a positive result (positive predictive value) if the
score is > 0. Extrapolating our ﬁndings to the validation set,
excluding patients with a score of 0 would have “saved” 11 patients
(18.9%) from undergoing biopsy with negative results and would
have only “missed” 3 (5.2%) biopsies with positive results,
increasing the positive yield from 69% to 84.1%. The model pre-
sents high internal validity, as determined by the AUC model
obtained when testing the ROC AUC in the test and validation sets,
which had very similar AUC values.
Our study had a number of limitations. The variety of treatments
received by the patients could have made our data set less homo-
geneous than that of other cohorts of biopsies performed in the
setting of clinical trials.16 Furthermore, our patient population
represented patients with advanced, CRPC and a high burden of
bone metastases. It remains unclear whether our BMB score would
be valid for patients with earlier disease stages. Finally, because all
biopsies were performed in a single center, validation of the score is
needed in independent centers for external validity of the score to be
established. The high consistency of the results between the test and
validation sets does, nevertheless, suggest the potential applicability
in other centers that regularly perform BMBs.
Our BMB score was developed by deﬁning positive BMBs as
those with any evidence of tumor cells found after hematoxylin-
eosin staining. The heterogeneity of the data set, which included
patients participating in different studies over several years, pre-
cluded the association of the score with the successful determination
of speciﬁc molecular biomarkers. However, previous studies
reporting an association of phosphatase and tensin homolog status
(determined in soft tissue biopsies and BMBs) and survival had
restricted evaluable samples to those with  50 tumor cells.18 We
have shown that our score is capable of discriminating those patients
likely to yield > 50 cells. In the validation set, the exclusion of
patients with a score of 0 would have increased the positivity yield
from 55.2% to 68.2%.
Conclusion
Performing serial BMBs in patients with mCRPC is a feasible
and valid approach for the acquisition of cancer tissue for molecular
analysis. We have presented a BMB score that demonstrates how
the use of imaging and laboratory parameters can help select patients
and increase the rate of positive biopsy specimens.
Clinical Practice Points
 Up to 90% of patients with advanced prostate cancer have dis-
ease metastatic to the bone, which is, in many cases, the only site
of metastatic disease.nical Genitourinary Cancer Month 2016 The development of circulating and tissue-based predictive bio-
markers such as AR-V7 splice variants or genomic aberrations of
DNA repair genes has been proposed for treatment selection in
advanced prostate cancer.
 Previous reports have established the yield of noneimage-guided
positive BMB specimens in 25% to 47% of cases.
 Using a score based on the CT HUs (mean HU > 125) and
LDH level (> 225 IU/L) can help select patients with an
increased likelihood of having a positive BMB specimen from the
iliac crest.
 Patients with a score of 0 (mean HUs < 125 and LDH < 225
IU/L) will have a very low BMB yield and should not be selected
for the procedure.
 Optimization of the methods for patient selection for a fresh
biopsy procedure could help in molecular stratiﬁcation and
adequate treatment selection for patients with mCRPC.Acknowledgments
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